The Aesthetic Guide is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Vollure: The new 18-month filler

Dr. GreenJuvéderm Vollure XC — It’s the first FDA-approved hyaluronic acid dermal filler for the correction of moderate to severe wrinkles and folds that lasts up to 18 months. And according to Michele S. Green, M.D., a cosmetic dermatologist in private practice in New York City, it’s revolutionary.

“These results are much better than I expected,” Dr.  Green tells Cosmetic Surgery Times. “The effect lasted so much longer than I thought it would. The duration of many aesthetic products in real life is less than what is claimed. To have a dermal filler last a solid 18 months is pretty revolutionary.”

Vollure uses Allergan’s proprietary VYCROSS technology, which, according to the company, blends various molecular weights of hyaluronic acid (HA) to help the gel achieve an impressive 18 months of duration on average.

As for the actual numbers, in the U.S. pivotal clinical trial, 59% of patients achieved improvement in moderate to severe nasolabial folds for up to 18 months; 82% of patients were very satisfied at 6 months and 68% at 18 months.

“[Vollure] is very malleable,” says Dr. Green, who points out that she was one of the first clinicians to use Vollure.. “When injecting, it truly has a natural feel as opposed to a thick filler. “The product offers both a much more natural look and feel.”

Vollure is similar to Voluma, which was Allergan’s first product to incorporate VYCROSS technology. “Voluma adds volume to a patient’s face, primarily in the cheek area,” according to Dr. Green.

Related: Avoiding complications with dermal fillers

VYCROSS is also found in Volbella, which is used to augment the lip and treat fine lines around the mouth.

Ideal candidates for Vollure are over the age of 35, with a significant nasolabial area that they desire to correct for the long term.

To enhance the efficacy and safety of Vollure, Dr. Green recommends injecting slowly. “I also mark the patient and evaluate the anatomy,” she says. “This is a filler that enters the skin in vascular areas; therefore, you do not want to risk any occlusion.”

Dr. Green anticipates a “huge” reception of Vollure by cosmetic doctors. “I envision that this filler will replace a lot of other injections because the main complaint of patients is that fillers do not last that long,” she says. 

Hide comments
account-default-image

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish